Editorial. Weighty matter

Editorial. Weighty matter

Semaglutide brands’ consumption needs monitoring

After the semaglutide molecule, used to treat type 2 diabetes and/or weight loss, went off patent last Friday, a flood of branded generics entered the market. The reaction has ranged from euphoria to… [+2836 chars]